WASHINGTON, Nov. 25, 2008 (GLOBE NEWSWIRE) -- Finkelstein Thompson LLP is investigating potential shareholder claims arising from the proposed acquisition of Alpharma, Inc. (NYSE:ALO) by King Pharmaceuticals, Inc. (NYSE:KG).
On November 24, 2008 the companies announced the signing of a definitive merger agreement under which King will acquire all the outstanding Class A shares of Alpharma for $37.00 cash per share. Both companies' Boards unanimously approved the transaction. Just two months ago, in September of 2008, the Alpharma board issued a letter to shareholders unanimously recommending that shareholders reject the $37.00 offer, stating that it was financially inadequate and not in the best interest of Alpharma's shareholders.
If you are an Alpharma shareholder, we welcome inquiries concerning your rights and interests in this matter. Please contact our Washington, D.C. office by calling us toll-free at (877) 337-1050, or by email at contact@finkelsteinthompson.com.
Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in connection with securities and other finance-related litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers. To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com.